NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/15/2026 15:37
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization4,427.49 mln
Float26.81 mln
Earnings Date08/06/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
161
Transformational upside
Relative Strength
13
/ 100
Significantly lagging
Debt / Equity
6.04
Extremely leveraged
ROE
-240
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Celcuity is a Minneapolis-based clinical-stage company founded in 2011 that develops precision treatments for solid tumors. Its primary focus is Gedatolisib, a drug designed to block key molecular pathways that drive advanced breast cancer and metastatic prostate cancer. The company holds a licensing agreement with Pfizer covering the development and commercialization of this drug candidate.
